Q2 2022 EPS Estimates for Profound Medical Corp. Cut by Analyst (TSE:PRN)

Profound Medical Corp. (TSE:PRN – Get Rating) – Stock analysts at Jefferies Financial Group cut their Q2 2022 earnings estimates for shares of Profound Medical in a research note issued to investors on Monday, May 9th. Jefferies Financial Group analyst Z. Weiner now anticipates that the company will post earnings of ($0.50) per share for the quarter, down from their previous estimate of ($0.41). Jefferies Financial Group also issued estimates for Profound Medical’s Q3 2022 earnings at ($0.37) EPS, Q4 2022 earnings at ($0.36) EPS, FY2022 earnings at ($1.75) EPS, FY2023 earnings at ($1.27) EPS and FY2024 earnings at ($0.29) EPS.

Profound Medical (TSE:PRN – Get Rating) last released its earnings results on Thursday, March 3rd. The company reported C($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.44) by C($0.18). The business had revenue of C$1.26 million for the quarter, compared to analyst estimates of C$3.52 million.

Separately, Raymond James restated a “buy” rating and set a C$23.00 price target on shares of Profound Medical in a report on Tuesday, February 22nd.

PRN opened at C$9.01 on Thursday. The company has a debt-to-equity ratio of 1.71, a current ratio of 18.56 and a quick ratio of 16.50. The company’s 50 day simple moving average is C$10.56 and its two-hundred day simple moving average is C$12.63. Profound Medical has a 1-year low of C$8.00 and a 1-year high of C$23.67. The firm has a market capitalization of C$187.23 million and a price-to-earnings ratio of -4.62.

Profound Medical Company Profile (Get Rating)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.

Featured Stories